High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/84082
Title:
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy.
Authors:
Lønning, Per E; Taylor, Paul; Anker, Gun; Iddon, Julie; Wie, Liv; Jørgensen, Linn-Marie; Mella, Olav; Howell, Anthony ( 0000-0002-3879-5991 )
Abstract:
Estrogens administered in high doses were commonly used for therapy of advanced breast cancer before the introduction of contemporary endocrine therapy. While the mechanism of the antitumor effect is unknown, in vitro investigations have shown estrogens in high concentrations to be toxic to cell growth. Further, it has been shown that exposure of MCF-7 cells to estrogens in low concentrations may enhance the sensitivity and also lower the toxicity threshold to estrogens. This study was designed to evaluate treatment with diethylstilbestrol (DES) in postmenopausal women with advanced breast cancer becoming resistant to estrogen deprivation. Thirty-two patients with advanced breast cancer previously exposed to multiple endocrine treatment regimens (median 4, range 2-10) were enrolled. Their tumor should have revealed evidence of endocrine sensitivity (previous partial response or at least stable disease for > or = 6 months to therapy). Each patient received DES 5 mg t.i.d. Four patients terminated therapy after < or = 2 weeks on therapy due to side effects; another two patients terminated therapy before progression for similar reasons (one patient after SD for 15 weeks and one with a PR after 39 weeks). Four patients obtained CR and six patients PR. In addition, two patients had SD for > or = 6 months duration. Five patients had an objective response and one patient a SD lasting for > or = 1 year. Our results reveal estrogens administered in high doses may have antitumor effects in breast cancer patients heavily pretreated with endocrine therapy. Such treatment represents a valuable alternative to chemotherapy in selected patients.
Affiliation:
Department of Medicine, Haukeland University Hospital, Bergen, Norway.
Citation:
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. 2001, 67 (2):111-6 Breast Cancer Res. Treat.
Journal:
Breast Cancer Research and Treatment
Issue Date:
May-2001
URI:
http://hdl.handle.net/10541/84082
PubMed ID:
11519859
Type:
Article
Language:
en
ISSN:
0167-6806
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLønning, Per Een
dc.contributor.authorTaylor, Paulen
dc.contributor.authorAnker, Gunen
dc.contributor.authorIddon, Julieen
dc.contributor.authorWie, Liven
dc.contributor.authorJørgensen, Linn-Marieen
dc.contributor.authorMella, Olaven
dc.contributor.authorHowell, Anthonyen
dc.date.accessioned2009-10-12T16:08:45Z-
dc.date.available2009-10-12T16:08:45Z-
dc.date.issued2001-05-
dc.identifier.citationHigh-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. 2001, 67 (2):111-6 Breast Cancer Res. Treat.en
dc.identifier.issn0167-6806-
dc.identifier.pmid11519859-
dc.identifier.urihttp://hdl.handle.net/10541/84082-
dc.description.abstractEstrogens administered in high doses were commonly used for therapy of advanced breast cancer before the introduction of contemporary endocrine therapy. While the mechanism of the antitumor effect is unknown, in vitro investigations have shown estrogens in high concentrations to be toxic to cell growth. Further, it has been shown that exposure of MCF-7 cells to estrogens in low concentrations may enhance the sensitivity and also lower the toxicity threshold to estrogens. This study was designed to evaluate treatment with diethylstilbestrol (DES) in postmenopausal women with advanced breast cancer becoming resistant to estrogen deprivation. Thirty-two patients with advanced breast cancer previously exposed to multiple endocrine treatment regimens (median 4, range 2-10) were enrolled. Their tumor should have revealed evidence of endocrine sensitivity (previous partial response or at least stable disease for > or = 6 months to therapy). Each patient received DES 5 mg t.i.d. Four patients terminated therapy after < or = 2 weeks on therapy due to side effects; another two patients terminated therapy before progression for similar reasons (one patient after SD for 15 weeks and one with a PR after 39 weeks). Four patients obtained CR and six patients PR. In addition, two patients had SD for > or = 6 months duration. Five patients had an objective response and one patient a SD lasting for > or = 1 year. Our results reveal estrogens administered in high doses may have antitumor effects in breast cancer patients heavily pretreated with endocrine therapy. Such treatment represents a valuable alternative to chemotherapy in selected patients.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectNon-Steroidal Oestrogensen
dc.subjectOestrogen Receptorsen
dc.subject.meshAdministration, Oral-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshBreast Neoplasms-
dc.subject.meshDiethylstilbestrol-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshDrug Resistance, Neoplasm-
dc.subject.meshEstrogens, Non-Steroidal-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.subject.meshPostmenopause-
dc.subject.meshReceptors, Estrogen-
dc.subject.meshReceptors, Progesterone-
dc.subject.meshTreatment Outcome-
dc.titleHigh-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, Haukeland University Hospital, Bergen, Norway.en
dc.identifier.journalBreast Cancer Research and Treatmenten

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.